Brokers Offer Predictions for Commonwealth Bank of Australia’s FY2022 Earnings (OTCMKTS:CSLLY)

Commonwealth Bank of Australia (OTCMKTS:CSLLY) – Research analysts at Jefferies Financial Group lowered their FY2022 earnings per share (EPS) estimates for Commonwealth Bank of Australia in a note issued to investors on Thursday, June 25th. Jefferies Financial Group analyst D. Stanton now expects that the company will post earnings per share of $2.84 for the year, down from their prior forecast of $2.85. Jefferies Financial Group currently has a “Hold” rating on the stock.

A number of other research firms also recently weighed in on CSLLY. Citigroup raised Commonwealth Bank of Australia from a “neutral” rating to a “buy” rating in a research report on Thursday, May 28th. Zacks Investment Research upgraded Commonwealth Bank of Australia from a “sell” rating to a “hold” rating in a research note on Monday. Finally, ValuEngine upgraded Commonwealth Bank of Australia from a “sell” rating to a “hold” rating in a research note on Thursday, April 2nd. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $110.00.

OTCMKTS:CSLLY opened at $100.51 on Monday. Commonwealth Bank of Australia has a twelve month low of $73.01 and a twelve month high of $114.40. The business has a 50 day moving average price of $98.24 and a two-hundred day moving average price of $99.54. The company has a market cap of $90.31 billion, a P/E ratio of 47.41 and a beta of 0.61.

Commonwealth Bank of Australia Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders.

Recommended Story: Inverted Yield Curve

Earnings History and Estimates for Commonwealth Bank of Australia (OTCMKTS:CSLLY)

Receive News & Ratings for Commonwealth Bank of Australia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Commonwealth Bank of Australia and related companies with MarketBeat.com's FREE daily email newsletter.